Levi & Korsinsky Urges APLT Shareholders to File Lead Plaintiff Applications Before February 2025 Deadline

APLT Class Action Lawsuit Alert

Levi & Korsinsky, LLP is reaching out to investors in Applied Therapeutics, Inc. (NASDAQ: APLT) regarding a significant class action securities lawsuit. This legal action is particularly relevant for shareholders who may have experienced financial losses as a result of alleged securities fraud that took place between January 3, 2024, and December 2, 2024.

Case Overview

The heart of this lawsuit stems from a press release issued by Applied Therapeutics on November 27, 2024. In this announcement, the company revealed that they had received a Complete Response Letter (CRL) from the FDA concerning their New Drug Application (NDA) for their flagship drug candidate, govorestat. The CRL indicated that the FDA found deficiencies in the clinical application of the drug, causing the company’s stock to drop significantly, from $10.21 per share on November 26 to $8.57 the following day. Continuing the downward trend, the stock plummeted further, reaching just $1.75 per share by December 2, representing a total decline of over 80%.

Dramatic shifts in stock price continued after Applied Therapeutics disclosed, post-market on December 2, that they had received a “warning letter” from the FDA. This letter referenced critical issues involved in their clinical trials, exacerbating the situation and triggering further declines in their stock price—in just a few days, shares fell to as low as $1.29.

What Are Your Rights?

For current or former shareholders of Applied Therapeutics who suffered losses within the stipulated timeframe, the important deadline to keep in mind is February 18, 2025. By this date, investors should request the court to appoint them as lead plaintiffs. Notably, participating in this class action does not require you to serve as a lead plaintiff; members may still be entitled to compensation regardless.

Zero Cost Participation

It’s important to highlight that participating in this class action involves no upfront costs. If you're identified as a class member, you could obtain compensation without incurring out-of-pocket fees, making the opportunity accessible to all impacted investors.

Why Choose Levi & Korsinsky?

With over 20 years of experience, Levi & Korsinsky has championed the rights of shareholders and recovered hundreds of millions of dollars on their behalf. The law firm has built an impressive track record of winning complex securities cases, recently earning recognition as one of the top litigation firms in the U.S. for several consecutive years.

How to Proceed

If you believe you qualify as a class member, you are encouraged to reach out promptly. You can contact Joseph E. Levi, Esq. at Levi & Korsinsky for more details to participate. You can also fill out their submission form to get in touch with their team.

Now is the time to secure your rights and potentially recover your losses related to Applied Therapeutics, Inc. Don’t miss this critical window!